多发性骨髓瘤的发生发展及治疗的生物学研究。
Biological research on the occurrence and development of multiple myeloma and its treatment.
机构信息
Department of Orthopaedics, Beijing Chao-Yang Hospital, Beijing, China.
出版信息
Immun Inflamm Dis. 2023 May;11(5):e850. doi: 10.1002/iid3.850.
INTRODUCTION
To review the pathogenesis and treatment of multiple myeloma (MM). MM is a hematological malignancy with abnormal plasma cell proliferation in bone marrow. Due to the emergence of drug resistance, MM is still an incurable malignancy, which requires further exploration of pathogenesis and effective therapeutic targets.
METHODS
In this paper, the method of literature review is adopted to obtain the information about MM. Based on the literature, comprehensive and systematic review is made.
RESULTS
MM is a complex pathophysiological process with great heterogeneity, mainly reflected in genomic instability and bone marrow microenvironment. At present, the treatment of MM has made great progress, proteasome inhibitors and immunomodulatory drugs are widely used in clinic. Allogeneic stem cell transplantation may be the only promising cure for MM, and its high transplant-related mortality limits its clinical application.
CONCLUSIONS
The future of MM treatment lies in the development of more targeted therapies, novel immunotherapies, and a better understanding of the disease's molecular and genetic basis.
简介
本文旨在综述多发性骨髓瘤（MM）的发病机制和治疗方法。MM 是一种血液系统恶性肿瘤，其特征为骨髓中异常浆细胞的增殖。由于耐药性的出现，MM 仍然是一种不可治愈的恶性肿瘤，这需要进一步探索发病机制和有效的治疗靶点。
方法
本文采用文献回顾的方法获取 MM 的相关信息。基于文献进行综合系统的回顾。
结果
MM 是一个具有高度异质性的复杂病理生理过程，主要表现为基因组不稳定性和骨髓微环境。目前，MM 的治疗已经取得了很大的进展，蛋白酶体抑制剂和免疫调节剂在临床上得到了广泛应用。异基因造血干细胞移植可能是 MM 唯一有希望的治愈方法，但较高的移植相关死亡率限制了其临床应用。
结论
MM 治疗的未来在于开发更有针对性的治疗方法、新型免疫疗法以及更好地理解疾病的分子和遗传基础。
Zotero 插件